Prism Medico and Pharmacy Ltd Stock Price Today (NSE: PRISMMEDI)
Prism Medico and Pharmacy Ltd
Fundamental Score
Prism Medico and Pharmacy Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Prism Medico and Pharmacy Ltd share price today is ₹27.14, down 3.42% on NSE/BSE as of 7 August 2026. Prism Medico and Pharmacy Ltd (PRISMMEDI) is a Small-cap company in the Non Banking Financial Company (NBFC) sector with a market capitalisation of ₹38.25 (Cr). The 52-week high for PRISMMEDI share price is ₹34.49 and the 52-week low is ₹13.02. At a P/E ratio of 119.54x, PRISMMEDI is currently trading above its industry average P/E of 22.18x. The company has a Return on Equity (ROE) of 2.10% and a debt-to-equity ratio of 0.00.
Prism Medico and Pharmacy Ltd Share Price Chart — NSE/BSE Historical Performance
Prism Medico and Pharmacy Ltd share price chart: 0.60% return over the past month. 52-week high ₹34.49, 52-week low ₹13.02.
Prism Medico and Pharmacy Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹28.96 | ₹28.96 | ₹27.50 | ₹28.10 | 6.01K (Cr) | |
| ₹29.99 | ₹29.99 | ₹27.02 | ₹27.74 | 13.30K (Cr) | |
| ₹28.90 | ₹30.99 | ₹27.61 | ₹29.32 | 4.58K (Cr) | |
| ₹30.02 | ₹30.02 | ₹27.60 | ₹28.90 | 6.64K (Cr) | |
| ₹28.98 | ₹29.50 | ₹27.51 | ₹28.67 | 12.31K (Cr) | |
| ₹28.41 | ₹29.41 | ₹27.30 | ₹27.53 | 2.42K (Cr) | |
| ₹28.98 | ₹28.98 | ₹27.16 | ₹28.41 | 225.00 (Cr) | |
| ₹29.15 | ₹29.15 | ₹26.31 | ₹28.27 | 2.76K (Cr) | |
| ₹26.50 | ₹28.90 | ₹25.00 | ₹27.04 | 16.47K (Cr) | |
| ₹30.40 | ₹30.40 | ₹27.05 | ₹29.23 | 805.00 (Cr) |
Prism Medico and Pharmacy Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹30.02 | ₹30.99 | ₹27.02 | ₹28.10 | -6.40% | |
| ₹28.98 | ₹30.40 | ₹25.00 | ₹28.67 | -1.07% | |
| ₹29.00 | ₹30.35 | ₹25.52 | ₹29.00 | +0.00% | |
| ₹31.30 | ₹32.00 | ₹27.35 | ₹30.00 | -4.15% | |
| ₹24.14 | ₹34.49 | ₹24.14 | ₹30.17 | +24.98% | |
| ₹30.22 | ₹30.22 | ₹22.48 | ₹25.21 | -16.58% | |
| ₹17.78 | ₹28.79 | ₹15.71 | ₹28.79 | +61.92% | |
| ₹19.78 | ₹20.35 | ₹15.51 | ₹16.62 | -15.98% | |
| ₹17.95 | ₹20.96 | ₹15.85 | ₹19.00 | +5.85% | |
| ₹19.25 | ₹20.88 | ₹17.90 | ₹17.95 | -6.75% | |
| ₹23.57 | ₹24.80 | ₹19.00 | ₹19.25 | -18.33% | |
| ₹18.25 | ₹22.50 | ₹15.65 | ₹22.50 | +23.29% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap NBFC hoping for a turnaround, but fundamentals are terrible and liquidity is a major concern.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Prism Medico and Pharmacy held an Extraordinary General Meeting (EGM) on March 20, 2026, where shareholders approved altering the Articles of Association and a preferential issue of equity shares and convertible warrants. On March 25, 2026, a bulk deal on BSE saw 90,000 shares traded at an average price of
CORE STORY (THE REAL GAME)
This is a micro-cap NBFC attempting a turnaround through capital restructuring. The market is likely pricing in the potential upside from the preferential issue and warrant conversion, but also the dilution risk.
- Shareholder approval for capital restructuring
- Recent bulk buying activity
- Positive NBFC sector sentiment
- Successful deployment of capital
- Significant improvement in financial performance
- New order wins or partnerships
- Micro-cap liquidity risk
- Negative ROE and ROCE
- Declining sales CAGR
- Significant YoY profit decline
Recent bulk deals show some interest, but no significant FII/DII activity. Promoter holding stable at 25%.
NBFC sector faces evolving regulations and potential headwinds from global economic uncertainty.
Poor. Free Cash Flow 5Y is only ₹0.49 Cr.
If the company can successfully raise and deploy capital, a turnaround is possible. However, execution risk is high, and the current financial situation is precarious.
Primary Thesis Risk
Failure to improve profitability and manage capital structure will lead to collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Prism Medico and Pharmacy Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Prism Medico and Pharmacy Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PRISMMEDI across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (300.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (34.86% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.86% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (2.10%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.82%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-2.55%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 119.54x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-700.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-31.98% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Prism Medico and Pharmacy Ltd vs Non Banking Financial Company (NBFC) Peers
Peer Comparison - Non Banking Financial Company (NBFC)
Compare Prism Medico and Pharmacy Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Prism Medico and Pharmacy LtdPrism Medico an...Selected✓ PRISMMEDI • 512217 | 25.4/100 | ₹27.14₹27 | ₹38.25₹38.25 | 119.54Average 119.5 Average | 2.10%Poor 2.10% Poor | 2.82%Poor 2.82% Poor | 0.00Excellent 0.0 Excellent | 34.86%Excellent 34.86% Excellent | -31.98%Poor -31.98% Poor | 0.00% |
Bajaj Finance LtdBajaj Finance L... BAJFINANCE • 500034 | 62.4/100 | ₹1141.20₹1141 | ₹635919.89₹635919.89 | 33.08Average 33.1 Average | 18.25%Good 18.25% Good | 10.87%Average 10.87% Average | 3.82Poor 3.8 Poor | 34.15%Excellent 34.15% Excellent | 25.18%Excellent 25.18% Excellent | 0.53% |
Shriram Finance LtdShriram Finance... SHRIRAMFIN • 511218 | 48.8/100 | ₹1046.70₹1047 | ₹243379.83₹243379.83 | 24.27Average 24.3 Average | 16.39%Good 16.39% Good | 11.49%Average 11.49% Average | 3.80Poor 3.8 Poor | 32.03%Excellent 32.03% Excellent | 22.54%Excellent 22.54% Excellent | 1.04% |
65.8/100 | ₹1849.90₹1850 | ₹153802.44₹153802.44 | 29.36Average 29.4 Average | 19.35%Good 19.35% Good | 9.71%Poor 9.71% Poor | 6.93Poor 6.9 Poor | 28.05%Excellent 28.05% Excellent | 26.56%Excellent 26.56% Excellent | 0.11% | |
Muthoot Finance LtdMuthoot Finance... MUTHOOTFIN • 533398 | 73.9/100 | ₹3119.60₹3120 | ₹121113.00₹121113.00 | 11.44Average 11.4 Average | 30.92%Excellent 30.92% Excellent | 15.77%Good 15.77% Good | 3.88Poor 3.9 Poor | 22.71%Excellent 22.71% Excellent | 22.03%Excellent 22.03% Excellent | 0.99% |
L&T Finance LtdL&T Finance Ltd... LTF • 533519 | 55.2/100 | ₹311.25₹311 | ₹78301.66₹78301.66 | 24.45Average 24.4 Average | 11.22%Average 11.22% Average | 8.40%Poor 8.40% Poor | 3.94Poor 3.9 Poor | 32.35%Excellent 32.35% Excellent | 6.05%Good 6.05% Good | 0.88% |
HDB Financial Services LimitedHDB Financial S... HDBFS • 544429 | 54.3/100 | ₹686.35₹686 | ₹62415.22₹62415.22 | 22.61Average 22.6 Average | 13.94%Average 13.94% Average | 9.09%Poor 9.09% Poor | 4.80Poor 4.8 Poor | 45.37%Excellent 45.37% Excellent | 10.99%Good 10.99% Good | 0.53% |
SBI Cards and Payment Services LtdSBI Cards and P... SBICARD • 543066 | 43.9/100 | ₹660.15₹660 | ₹60979.59₹60979.59 | 28.14Average 28.1 Average | 14.69%Average 14.69% Average | 10.10%Average 10.10% Average | 2.80Poor 2.8 Poor | 17.08%Excellent 17.08% Excellent | 16.43%Excellent 16.43% Excellent | 0.39% |
Sundaram Finance LtdSundaram Financ... SUNDARMFIN • 590071 | 29.5/100 | ₹4665.60₹4666 | ₹50074.63₹50074.63 | 23.75Average 23.8 Average | 15.01%Good 15.01% Good | 9.44%Poor 9.44% Poor | 4.68Poor 4.7 Poor | 12.69%Good 12.69% Good | 13.23%Good 13.23% Good | 0.89% |
23.9/100 | ₹539.30₹539 | ₹42560.25₹42560.25 | 22.04Average 22.0 Average | 13.13%Average 13.13% Average | 13.67%Average 13.67% Average | 0.23Excellent 0.2 Excellent | — — | — — | 0.04% | |
Poonawalla Fincorp LtdPoonawalla Finc... POONAWALLA • 524000 | 54.9/100 | ₹463.55₹464 | ₹41881.04₹41881.04 | 77.14Average 77.1 Average | 5.86%Poor 5.86% Poor | 7.51%Poor 7.51% Poor | 4.68Poor 4.7 Poor | 24.33%Excellent 24.33% Excellent | 23.97%Excellent 23.97% Excellent | 0.00% |
Top Non Banking Financial Company (NBFC) Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Bajaj Finance Ltd share price635919.89 Cr
- Shriram Finance Ltd share price243379.83 Cr
- Cholamandalam Investment and Finance Company Limited share price153802.44 Cr
- Muthoot Finance Ltd share price121113.00 Cr
- L&T Finance Ltd share price78301.66 Cr
Prism Medico and Pharmacy Ltd Quarterly Performance
Latest quarterly metrics for PRISMMEDI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
300.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-700.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-31.98%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.86%
Compounded annual net profit growth over 5 years
Prism Medico and Pharmacy Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PRISMMEDI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Prism Medico and Pharmacy Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Prism Medico and Pharmacy Ltd (PRISMMEDI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Prism Medico and Pharmacy Ltd
About PRISMMEDI (Prism Medico and Pharmacy Ltd)
Prism Medico and Pharmacy Ltd is a Non-Banking Financial Company (NBFC) based in India, focused on providing financial solutions tailored for the healthcare and pharmaceutical sect...ors. Originally established in 1985, the company has evolved from its earlier mercantile operations to specialize in the unique financial needs of medical professionals, pharmacies, and healthcare-related businesses. PRISMMEDI's core business involves extending credit and financial products that support the growth and operational efficiency of entities within the medical ecosystem. This includes financing for equipment procurement, infrastructure development, working capital management, and expansion plans for clinics, hospitals, and pharmacies. The company's commitment is to drive advancement within the Indian healthcare industry by facilitating access to capital and resources. PRISMMEDI operates with a deep understanding of the specific financial challenges faced by the medical community. This understanding allows the company to design financial products and services that are not only accessible but also strategically aligned with the long-term goals of its clients. Beyond lending, PRISMMEDI also offers financial advisory services to help its clients navigate complex financial landscapes, optimize their resource allocation, and make informed investment decisions. By taking a holistic approach to financial support, the company strives to be more than just a lender; it aims to be a trusted partner in its clients' success. PRISMMEDI distinguishes itself through specialized domain knowledge and customized service. The company is dedicated to fostering sustainable growth in the healthcare sector by empowering its clients with the necessary financial tools. PRISMMEDI focuses on building long-term relationships, understanding the unique needs of each client and creating customized financial solutions. With its established presence in India and commitment to providing reliable financial services, PRISMMEDI is positioned to play a significant role in the advancement of Indian healthcare. The company continuously explores innovative approaches to address the changing financial needs of the sector and remains dedicated to upholding the highest standards of integrity and ethical conduct in its operations.
Company Details
Key Leadership
PRISMMEDI Share Price: Frequently Asked Questions
What is the current share price of Prism Medico and Pharmacy Ltd?
Prism Medico and Pharmacy Ltd (PRISMMEDI) trades at ₹27.14 on NSE and BSE. Market cap ₹38.25 (Cr). Educational data only.
What is the P/E ratio of Prism Medico and Pharmacy Ltd?
Prism Medico and Pharmacy Ltd has a P/E of 119.54x vs industry average 22.18x.
What is the Bull Run score for Prism Medico and Pharmacy Ltd?
Prism Medico and Pharmacy Ltd has a Bull Run score of 25.4/100 based on 25+ financial parameters.
Does Prism Medico and Pharmacy Ltd pay dividends?
Prism Medico and Pharmacy Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Prism Medico and Pharmacy Ltd?
Prism Medico and Pharmacy Ltd has ROE of 2.10%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Prism Medico and Pharmacy Ltd?
Prism Medico and Pharmacy Ltd has debt-to-equity of 0.00.
Is Prism Medico and Pharmacy Ltd a good investment?
Bull Run gives Prism Medico and Pharmacy Ltd a score of 25.4/100. This is not investment advice — consult a SEBI-registered advisor.